



WE CLAIM:

1. A compound of formula (Ia), formula (Ib), formula (IIa) or formula (IIb):



Formula (I)




Formula (II)


or a pharmaceutically acceptable salt thereof:

wherein:

m is 0, 1, 2 or 3;



is selected from the group consisting of:



each R^1 is independently halogen, -CN, C_1 - C_3 alkyl, haloalkyl, alkyl-OH, $-N(R^4)_2$, $-NR^4C(O)C_1$ - C_3 alkyl, -OH, -O-alkyl, or cycloalkyl;


R^2 is H or halogen;

R^3 is H, halogen or C_1 - C_3 alkyl;


each R^4 is independently H or C_1 - C_3 alkyl; and

Y is CH or N.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein



is selected from the group consisting of:



3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein




4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein m is one.
5. The compound of claim 1, wherein R^1 is chlorine or fluorine.
6. The compound of claim 4, wherein R^1 is trifluoromethyl.
7. The compound of claim 1, wherein the each R^4 group of the $-N(R^4)_2$ is hydrogen.
8. The compound of claim 1, wherein the each R^4 group of the $-N(R^4)_2$ is C1-C3 alkyl.
9. The compound of claim 1, wherein R^1 is hydroxymethyl.
10. The compound of claim 1, wherein R^1 is cyclopropyl.

11. The compound of claim 3, wherein m is two and each R¹ is independently cyano, halogen, C₁-C₃ alkyl or cycloalkyl.

12. The compound of claim 11, wherein each R¹ is halogen.

13. The compound of claim 11, wherein one R¹ is cyano and the other R¹ is hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C₁-C₃ alkyl, -N(R⁴)₂, -NR⁴C(O)C₁-C₃ alkyl or cycloalkyl.

14. The compound of claim 1, wherein



each R¹ is independently H or CH₃.

15. The compound of claim 14, wherein each R¹ is methyl.

16. The compound according to any one of claims 1-15, wherein R² is halogen.


17. The compound of claim 16, wherein the halogen is chlorine.


18. The compound according to any one of claims 1-17, wherein R³ is halogen or C₁-C₃ alkyl.

19. The compound of claim 18, wherein the halogen is fluorine.

20. The compound of claim 18, wherein the C₁-C₃ alkyl is methyl.

21. The compound of claim 1, wherein the compound is selected from the group consisting of:





and pharmaceutically acceptable salts thereof.

22. A pharmaceutical composition, comprising an effective amount of a compound according to any one of claims 1-21, and a pharmaceutically acceptable excipient.
23. Use of a therapeutically effective amount of a compound of claim 1 in the manufacture of a medicament for inhibiting ROCK activity in a cell, wherein the cell is to be contacted with the compound.
24. The use of claim 23, wherein the contacting occurs in vivo.
25. The use of claim 23 or 24, wherein the therapeutically effective amount of the compound is between 0.01 to 300 mg/kg per day.
26. The use of claim 25, wherein the therapeutically effective amount of the compound is between 0.1 to 100 mg/kg per day.
27. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating cerebral cavernous malformation syndrome (CCM) in a patient.
28. The use of Claim 27, wherein the therapeutically effective amount of the compound is between 0.01 to 300 mg/kg per day.
29. The use of Claim 28, wherein the therapeutically effective amount of the compound is between 0.1 to 100 mg/kg per day.

30. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating a cardiovascular disease associated with increased vasotension in a patient in need thereof.
31. The use of claim 30, wherein the cardiovascular disease is hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina or erectile dysfunction.
32. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating diseases involving elevated non-vascular smooth muscle contractility in a patient in need thereof.
33. The use of claim 32, wherein the disease involving elevated non-vascular smooth muscle contractility is asthma or glaucoma.